Printer Friendly

Sankyo to Launch Osteoporosis Treatment Drug in Europe.

Tokyo, Japan, July 19, 2006 - (JCN) - Daiichi Sankyo Europe GmbH, a wholly owned subsidiary of Sankyo Co. Ltd., have agreed with Eli Lilly on the launch of EVISTA (raloxifene), a new drug that helps prevent osteoporosis and can only be taken after menopause.

Raloxifene is a selective estrogen receptor modulator, specifically developed to maintain beneficial estrogenic activity on bone and lipids and antiestrogenic activity on endometrial and breast tissue.

It slows bone loss and slightly increases normal bone growth. Because of its tissue selectivity, raloxifene may have fewer side effects than are typically observed with estrogen therapy including vaginal bleeding and breast tenderness.

There still needs more proof that raloxifene can also prevent bone fractures or lowers the risk of heart disease.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Jul 19, 2006
Words:132
Previous Article:Trans Genic and Kumamoto Foundation Conclude Anti-HIV Antibody License Agreement.
Next Article:Yano Research Institute Surveys on One-Seg.
Topics:


Related Articles
Rebuilding strong bones.
ACTONE OFFERED FOR PREVENTION/TREATMENT OF OSTEOPOROSIS.
LILLY'S TERIPARATIDE GETS POSITIVE OPINION FROM EUROPEAN CPMP.
Sankyo Ceases Clinical Studies of Pactimibe, Investigational Drug for ASCVD.
Sankyo Licenses Cardiovascular Disease Drug Candidate KAI-9803 from KAI Pharmaceuticals.
Sankyo to Supply Hyperlipidemia Drug Pravastatin in US.
Sankyo to Manufacture, Distribute Olmetic Antihypertensive Drug in China.
Chugai Announces Co-Development and Co-Marketing Agreement with Taisho Pharmaceutical for the Antiresorptive Bisphosphonate R484.
Daiichi Sankyo Announces Completion of Phase I Trial on the Anti-influenza Drug CS-8958.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |